Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 17,926 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Nutritional and Metabolic Disease Clear all
Completed Not applicable Interventional Results available

Hybrid Argon Plasma Coagulation and Endoscopic Sleeve Gastroplasty Trial

NCT05559866
View directory record Official record
Conditions
Obesity
Interventions
Apollo ESG with ERBE HAPC, Apollo ESG
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The mFIT Study (Motivating Families With Interactive Technology)

NCT02361151
View directory record Official record
Conditions
Obesity
Interventions
TECH+
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
9 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 14, 2026, 9:03 AM EDT
Terminated Phase 1 Interventional

Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis

NCT03757351
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
DNL747, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Orlando, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 14, 2026, 9:03 AM EDT
Enrolling by invitation Not applicable Interventional

Population Health Management for KPNC Members With Newly Diagnosed Diabetes: A Randomized Trial of a Proactive and Augmented Initial Care Strategy

NCT06906653
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes (T2D)
Interventions
Augmented Initial Type 2 Diabetes Care
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 74 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Not applicable Interventional Results available

Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes

NCT03258853
View directory record Official record
Conditions
Cystic Fibrosis-related Diabetes
Interventions
Bionic Pancreas, Usual Care
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
10 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 14, 2026, 9:03 AM EDT
Terminated Phase 4 Interventional Results available

Treatment of GLP-1 for Diabetic Bariatric Patients

NCT04624672
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide (1 Mg Dose), Placebo
Drug
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 14, 2026, 9:03 AM EDT
Recruiting Not applicable Interventional

SPARK-CGM Implementation

NCT07548372
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Enhanced CGM Interventions, Standard of Care
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Not applicable Interventional

Feasibility of Delivering a Complex Behavioral Intervention for Young Adults With Diabetes Via Telehealth

NCT03333772
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
REAL-T Intervention
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 30 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 14, 2026, 9:03 AM EDT
Recruiting Not applicable Interventional

Closed Loop Context Aware AID

NCT06676657
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
iPancreas automated insulin delivery system
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 14, 2026, 9:03 AM EDT
Active, not recruiting Phase 2 Interventional

Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant

NCT03924401
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Abatacept
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 20 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Wilmington, Delaware • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 1 Interventional

Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID)

NCT00028236
View directory record Official record
Conditions
Severe Combined Immunodeficiency
Interventions
Gene-Transduced Autologous CD34+ Stem Cells
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Months to 20 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

NCT01730534
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event
Interventions
Dapagliflozin 10 mg, Placebo tablet
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
17,190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
234
States / cities
Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 202 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 14, 2026, 9:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Fatty Acid Regulation of Platelet Function in Diabetes

NCT02373332
View directory record Official record
Conditions
Thrombosis, Type 2 Diabetes Mellitus
Interventions
omega-3 and -6 fatty acids and their 12-LOX oxylipins
Other
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
2
States / cities
Ann Arbor, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Treating Obese and Lean Patients With Sleep Apnea

NCT01578031
View directory record Official record
Conditions
Sleep Apnea, Obesity
Interventions
Positive Airway Pressure During Sleep (ResMed S9 Elite), Usual Care
Device · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Not applicable Interventional

Nutrition and Coping Education for Symptom and Weight Management for Fibromyalgia

NCT00925431
View directory record Official record
Conditions
Fibromyalgia, Obesity
Interventions
Lifestyle Modification, Supportive education
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
21 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 14, 2026, 9:03 AM EDT
Terminated Phase 4 Interventional

Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding

NCT01597531
View directory record Official record
Conditions
Type 2 Diabetes, Gastric Banding
Interventions
Liraglutide, Orlistat, Liraglutide + Orlistat
Drug
Lead sponsor
East Carolina University
Other
Eligibility
25 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 14, 2026, 9:03 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

The Effect of Adiposity on Muscle and Microvascular Function in HFpEF

NCT06930495
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions
Weight loss SOC Treatment with second generation anti-diabetic medications
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

NCT01105975
View directory record Official record
Conditions
Dyslipidemia
Interventions
LY2484595, Atorvastatin, Simvastatin, Rosuvastatin, Placebo for LY2484595, Placebo for Statins
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
38
States / cities
Fayetteville, Arkansas • San Diego, California • Spring Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 14, 2026, 9:03 AM EDT
Recruiting Phase 2 Interventional

MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men

NCT06031428
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
MANAGe-DM - novel nurse case management, Monthly Educational Mailing
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 14, 2026, 9:03 AM EDT
Recruiting No phase listed Observational

Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors

NCT05611307
View directory record Official record
Conditions
Testicular Cancer, Survivorship, ASCVD, Coronary Artery Disease, Lipid Disorder, Hypogonadism, Male, Cisplatin Adverse Reaction, Bone Marrow Transplant Complications
Interventions
Lipid profile, Coronary artery assessment, Hormone levels for hypogonadism
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 14, 2026, 9:03 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Study of Trilipix Effects on Lipids and Arteries

NCT01025492
View directory record Official record
Conditions
Dyslipidemia
Interventions
Trilipix, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
30 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 14, 2026, 9:03 AM EDT
Not yet recruiting Phase 3 Interventional

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

NCT07668336
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Orforglipron, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
17
States / cities
Sacramento, California • San Diego, California • Stamford, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Molecular Mechanisms of Antipsychotic-induced Insulin Resistance

NCT02708394
View directory record Official record
Conditions
Adverse Effect of Other Antipsychotics and Neuroleptics, Insulin Resistance
Interventions
olanzapine, placebo
Drug
Lead sponsor
Wayne State University
Other
Eligibility
21 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 14, 2026, 9:03 AM EDT
Withdrawn Not applicable Interventional

Developing a Model to Predict Inpatient Hypoglycemic Episodes

NCT05989256
View directory record Official record
Conditions
Hypoglycemic Events, Hyperglycemic Therapy
Interventions
EndoTool, glucose management team, standard of care glucose management
Diagnostic Test · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 14, 2026, 9:03 AM EDT